Article info

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

Authors

  1. Correspondence to Dr Se Joon Woo, Department of Ophthalmology, Seoul National University College of Medicine, Seoul 13620, The Republic of Korea; sejoon1{at}snu.ac.kr
View Full Text

Citation

Bressler NM, Veith M, Hamouz J, et al
Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

Publication history

  • Received May 12, 2021
  • Accepted September 23, 2021
  • First published October 16, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.